Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MTX-COVAB

            Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 03, 2020

            Details:

            In the hamster challenge model, even low MTX-COVAB (5 mg/kg preventive; 10 mg/kg therapeutic) protected against weight loss, a key indicator of disease severity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AM-301

            Therapeutic Area: Infections and Infectious Diseases Product Name: AM-301

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            Daily treatment with AM-301, beginning right before inoculation, showed effective protection against viral infection. Up to 99.4% reduction of viral titer in human epithelial cell culture was observed after treatment with AM-301 in the study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Murepavadin

            Therapeutic Area: Infections and Infectious Diseases Product Name: POL7080

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: CF Foundation

            Deal Size: $3.3 million Upfront Cash: Undisclosed

            Deal Type: Funding November 24, 2020

            Details:

            Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AdCOVID

            Therapeutic Area: Infections and Infectious Diseases Product Name: AdCOVID

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Altimmune

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 10, 2020

            Details:

            Altimmune's agreement with Lonza expands its current clinical and commercial manufacturing strategy for AdCOVID. AdCOVID, a single-dose intranasal vaccine for COVID-19, designed to generate a broad immune response with the unique ability to promote nasal mucosal immunity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MP0420

            Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $231.0 million Upfront Cash: $22.0 million

            Deal Type: Licensing Agreement October 28, 2020

            Details:

            Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Thanatin-derivative antibiotic

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: CARB-X

            Deal Size: $18.4 million Upfront Cash: Undisclosed

            Deal Type: Funding October 14, 2020

            Details:

            Award will support the development of the “thanatin derivatives program” belonging to Polyphor’s novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MP0420

            Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            DARPin® candidates targeting SARS-CoV-2 show robust activity in an aggressive viral challenge hamster model, supporting potential efficacy as therapeutic options in patients with late-stage disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Linoleic Acid

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            The team found out that linoleic acid synergizes with currently utilized COVID-19 therapeutics to suppress replication and shut down the virus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AM-301

            Therapeutic Area: Infections and Infectious Diseases Product Name: AM-301

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            AM-301 is a gel which works by forming a protective layer on the nasal mucosa, acting as a physical barrier against airborne pathogens and allergens.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MP0420

            Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Swiss Government

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 11, 2020

            Details:

            Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both therapeutic and potential prophylactic use.

            PharmaCompass